Immunotherapies

Therapy Areas

Drug Classes

Therapy Areas

All Sessions

Resectable NSCLC

Advanced NSCLC

SCLC

Biomarkers

Drug Classes

Targeted Therapies

ADCs

All

FEATURED

ILCS

Webinars

Articles

Industry Sponsored

Featured Sessions

Prof. Alessandra Curioni-Fontecedro discussing approaches in metastatic PD-L1 negative NSCLC

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro

From Our Annual Summit

ILCS Sessions

Sep 26 2025

ILCS 2025

Immunotherapies

The Role of IO Added to Chemoradiation in Unresectable Stage III NSCLC

} 28 min

Tailoring IO in Res. NSCLC: Personalized Approaches for Improved Outcomes

} 36 min

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

} 25 min

J. Remon

Expert Insights

Webinars

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin

Dec 18 2025

VIRTUAL ROUNDTABLE

Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck

IO in NSCLC by Solange Peters, Jordi Remon, Patrick Forde

Jun 25 2025

VIRTUAL ROUNDTABLE

Advanced NSCLCImmunotherapies

Immunotherapies in NSCLC

} 1h 47 min

P. FordeJ. RemonS. Peters

SCLC by Solange Peters, Giannis Mountzios, Jacob Sands

Jun 17 2025

VIRTUAL ROUNDTABLE

SCLCImmunotherapies

Small Cell Lung Cancer

} 1h 35 min

G. MountziosJ. SandsS. Peters

The Reading Room

Articles & Research

Sep 09 2026

IMMUNOTHERAPIES

Advanced NSCLCImmunotherapies

HARMONi primary analysis reports 6.8 against 4.4 months PFS for ivonescimab plus chemotherapy after EGFR TKI progression

Sep 08 2026

IMMUNOTHERAPIES

Advanced NSCLCImmunotherapies

Pleural metastases carried worse two-year survival than contralateral lung metastases in stage M1a NSCLC

L. Hendriks

Sep 03 2026

IMMUNOTHERAPIES

Advanced NSCLCImmunotherapies

Akeso reports an OS benefit for ivonescimab over pembrolizumab in PD-L1-positive NSCLC

Sep 02 2026

IMMUNOTHERAPIES

Advanced NSCLCImmunotherapies

AI-HOPE registry recruits 920 patients to build machine-learning models for metastatic NSCLC outcomes

R. FerraraL. Hendriks

Aug 27 2026

ADCs, IMMUNOTHERAPIES, TARGETED THERAPIES

Advanced NSCLCADCsImmunotherapies

Two EORTC questionnaires cover the common side effects in NSCLC labels, and miss 62 rarer ones

J. RemonR. Ferrara

Aug 25 2026

IMMUNOTHERAPIES

Advanced NSCLCBiomarkersImmunotherapies

Cleared ctDNA within weeks predicted longer survival on immunotherapy in a 109-patient study

P. Forde

Aug 21 2026

IMMUNOTHERAPIES

Advanced NSCLCBiomarkersImmunotherapies

A ctDNA tumour fraction of 5 percent or more marks the patients who benefit from adding chemotherapy to checkpoint blockade

D. Planchard

Aug 19 2026

IMMUNOTHERAPIES

BiomarkersResectable NSCLCImmunotherapies

AIOT expert panel endorses chemo-immunotherapy as a new standard in resectable stage II-III NSCLC

T. CasconeP. FordeA. Passaro

Industry Sponsored

Featured Sessions

May 04 2026

Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro

Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.

A. Curioni-Fontecedro